Kymera Therapeutics (KYMR)

Healthcare · Biotechnology
$105.98 -3.52% on the day Market cap $8.2B 52-week range $55.26 to $130.05 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Kymera Therapeutics's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

D

Five factors scored 1 to 9 from KYMR's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation2
Profitability0
Growth9
Financial health9
Cash efficiency0

Key numbers

P/E (trailing)—
P/E (forward)0.00x
Price / free cash flow—
EV / EBITDA-9.49x
Price / sales78.2x
Price / book5.34x
Revenue growth+466.4%
Operating margin-333.5%
Net margin-285.3%
Return on equity-19.9%
Dividend yield—
Debt / equity0.09x

Results from SEC filings

Fiscal years, from Kymera Therapeutics's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$73M$47M$79M$47M$39M
Net income-$100M-$155M-$147M-$224M-$311M
Free cash flow-$131M-$156M-$137M-$207M-$234M
EPS (diluted)-$2.09-$2.87-$2.52-$2.98-$3.69
Operating margin-138.0%-344.4%-210.6%-555.8%-891.1%

Superinvestors who own KYMR

From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Hersh Cohen
ClearBridge Investments
New position $40M0.03%Q2 2026
Ron Baron
Baron Capital (BAMCO)
Held $2M0.00%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed $1M0.0%Q2 2026

Insider buying

Open-market purchases by Kymera Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of KYMR in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when KYMR trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Kymera Therapeutics insiders buying the stock?

No open-market insider purchases of KYMR in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Kymera Therapeutics?

3 of the superinvestors Investingly tracks hold KYMR in their latest 13F, including Hersh Cohen, Ron Baron, Cliff Asness.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.